Please select the eligibility criteria that correspond to the clinical trial below.
Title: Supplementation of Vitamin D in Preterm Infants- Monitored Therapy vs Standard Therapy. A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine wheather the monitored vitamin D (vit D) therapy is safer and more effective than standard therapy in pretrem infants.


Options:
A: Inclusion Criteria:

* Infants aged 1-24 months of age, diagnosed clinically as acute bronchiolitis and presented with any of the following:

  1. Persistent resting oxygen saturation below 92% in room air.
  2. Marked tachypnea.
  3. Intercostal retractions indicating respiratory distress.
  4. Inability to maintain oral hydration.
  5. Parent unable to care for child at home.

Exclusion Criteria:

1. Infants with history of prematurity (\< 37 weeks), chronic cardiopulmonary disease, immunodeficiency, neuromuscular disease, and any other chronic medical condition.
2. Patients receiving any micronutrient supplementation or therapies containing vitamin D for 4 weeks prior to the study period.
3. Infants with previous episodes of wheezing or a physician's diagnosis of asthma.
4. Patients with acute bronchiolitis having very severe clinical score.
B: Inclusion Criteria:

* Term infant
* No major congenital malformations
* Less than one month old
* Breastfed, no other foods

Exclusion Criteria:

* Formula feeding
* Premature birth
C: Inclusion Criteria:

* Diagnosis of sickle cell disease (HbSS, HbSC, HbS Beta-thalassemia)
* Age 3 to 20 years old

Exclusion Criteria:

* Patient (or parent or guardian) unwilling or unable to provide written informed consent (and assent, if applicable)
* Patient unable or unwilling to comply with requirements of the clinical trial
* Participation in other therapeutic clinical trial
* Current diagnosis of rickets
* History of hypercalcemia or diagnosis of any medical condition associated with hypercalcemia, including primary hyperparathyroidism, malignancy, sarcoidosis, tuberculosis, granulomatous disease, familial hypocalciuric hypercalcemia
* Current use of corticosteroids, excluding inhaled steroids
* Current use of anticonvulsants (phenytoin, phenobarbital, carbamazepine)
* Therapy with thiazide diuretics or lithium carbonate
* Known liver or renal disease
* Patients taking medications for pulmonary complications of sickle cell disease not on a stable dose of medications, as defined by a change in medications or doses within the three months prior to study entry
* Patients on chronic red blood cell transfusion therapy
* Absence of baseline record of respiratory events (respiratory infections, asthma exacerbations, episodes of acute chest syndrome) for the preceding year
* Pregnancy
D: Inclusion Criteria:

* Preterm infants born between 24 and 32 weeks of gestation (estimated by ultrasound)
* In born or admitted to the unit within 48hours from birth.
* Randomization within 7 days from birth.
* Parental consent.
* Mothers willing to return for follow up visits.

Exclusion Criteria:

* Preterm delivery \>=33 weeks of gestation or term delivery (estimated by ultrasound).
* Major congenital abnormalities.
* Participation in another trial.
* Severe illness at birth deemed incompatible with survival.
* Congenital HIV infection.
* Total parenteral nutrition \> 14 days.
* Cholestasis

Answer: D